eXoZymes, Inc.

NASDAQ:EXOZ

Biotechnology

Healthcare
$5.54 +16.75%

+$1.06 today

Market cap
$51.42M
Beta
2.66
P/E (TTM)
-6.5
EPS (TTM)
-$1.14
52W Low $6.33High $18.40

Volume 0.01M

Average 0.01M

EXOZ Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

eXoZymes, Inc.NASDAQ: EXOZ

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $501.1K rose 57.9% year over year, behind the +67.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 26.1% from the prior quarter. Over 3 fiscal years it compounded at +109.4% a year.

Context

  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +57.9% toward the trailing-twelve-month pace of +67.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$501.1K-26.1% QoQ
Last fiscal yearDec 2025
$1.99M+76.6% YoY
LTMMar 2026
$2.17M+67.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57.9%——
1 year+76.6%——
3-year CAGR+109.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
1.99M USD
Year-over-year change
+76.6%
4-year CAGR
+77.9%

Stock-Based Compensation vs competitors

How EXOZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +67.1% is the 2nd highest of 6, against a peer median of -42.1%.
  • Over three fiscal years its annual growth of +109.4% compares with a peer median of -5.3%.
EXOZ Competitors
Stock-Based Compensation for EXOZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$6.75M CAD+101.1%+21.4%—
TILInstil Bio, Inc.LTM Mar 2026$6.18M USD-61.9%-34.1%—
SRZNSurrozen, Inc.LTM Mar 2026$5.11M USD+30.3%-5.3%68.1%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$4.63M USD-43.5%+57.4%—
EXOZeXoZymes, Inc.LTM Mar 2026$2.17M USD+67.1%+109.4%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$1.83M USD-42.1%-16.4%—
TLSATiziana Life Sciences LtdFY2025$0 USD———
Peer median (excluding EXOZ) —-42.1%-5.3%68.1%

Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.21M)(1.4M)(2.04M)(5.86M)(9.16M)
Depreciation & Amortization59.41K147.75K196.94K267.38K(52.91K)
Deferred Income Tax00000
Stock-Based Compensation198.46K216.5K281.54K1.13M1.99M
Change in Working Capital(536.48K)(190.07K)220.31K(4.02M)380.17K
Accounts Receivables(317.07K)(341.18K)(72.79K)145.04K114.72K
Inventory00000
Accounts Payables(214.43K)118.5K272.89K221.34K311.09K
Other Working Capital(4.99K)32.61K20.21K(4.38M)(45.63K)
Other Non-Cash Items(99K)(35.15K)158.73K(19.4K)341.33K
Operating Cash Flow(1.59M)(1.26M)(1.18M)(8.51M)(6.5M)
Capital Expenditures(422.59K)(185.98K)(288.71K)(396.45K)(169.92K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities110.33K98.77K(22.46K)37.24K19.7K
Investing Cash Flow(312.25K)(87.21K)(311.17K)(359.22K)(150.22K)
Debt Repayment0003.98M(27.71K)
Common Stock Issued2.31M1.36M014.53M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities001M11.82K0
Financing Cash Flow2.31M1.36M1M18.52M(27.71K)
Effect of Forex Changes00000
Net Change in Cash413.45K10.76K(492.04K)9.65M(6.68M)
Free Cash Flow(2.01M)(1.44M)(1.47M)(8.9M)(6.67M)

eXoZymes, Inc.

NASDAQ:EXOZ

Intrinsic Alpha fair value

Locked

Current Price

$5.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.